|Bid||0.0000 x 1100|
|Ask||0.0000 x 3200|
|Day's Range||4.6500 - 5.0400|
|52 Week Range||3.6300 - 22.4800|
|Beta (5Y Monthly)||0.84|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Here's a roundup of top developments in the biotech space over the last 24 hours.Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 24) * Beigene Ltd (NASDAQ: BGNE)) * Forte Biosciences Inc (NASDAQ: FBRX) * Pacific Biosciences of California Inc (NASDAQ: PACB)Down In The Dumps (Biotech Stocks Hitting 52-week Lows Sept. 24) * ADiTx Therapeutics Inc (NASDAQ: ADTX) * AEterna Zentaris Inc. (NASDAQ: AEZS) * Akebia Therapeutics Inc (NASDAQ: AKBA) * Alector Inc (NASDAQ: ALEC) * AnPac Bio-Medical Science Co Ltd - ADR (NASDAQ: ANPC) * Amarin Corporation plc (NASDAQ: AMRN) * Athira Pharma Inc (NASDAQ: ATHA) * BELLUS Health Inc (NASDAQ: BLU) * Corbus Pharmaceuticals Holdings Inc (NASDAQ: CRBP) * Cyclacel Pharmaceuticals Inc (NASDAQ: CYCC) * DBV Technologies ADR Representing 0.5 Ord Shs (NASDAQ: DBVT) * Evofem Biosciences Inc (NASDAQ: EVFM) * Fusion Pharmaceuticals Inc (NASDAQ: FUSN) * Genetron Holdings Ltd - ADR (NASDAQ: GTH) * Genfit SA (NASDAQ: GNFT) * Gritstone Oncology Inc (NASDAQ: GRTS) * Happiness Biotech Group Ltd (NASDAQ: HAPP) * Histogen Inc (NASDAQ: HSTO) * Hoth Therapeutics Inc (NASDAQ: HOTH) * Intercept Pharmaceuticals Inc (NASDAQ: ICPT) * Jaguar Health Inc (NASDAQ: JAGX) * Lexicon Pharmaceuticals, Inc. (NASDAQ: LXRX) * Natus Medical Inc (NASDAQ: NTUS) * Neos Therapeutics Inc (NASDAQ: NEOS) * Neurobo Pharmaceuticals Inc (NASDAQ: NRBO) * NextCure Inc (NASDAQ: NXTC) * Odonate Therapeutics Inc (NASDAQ: ODT) * Oncternal Therapeutics Inc (NASDAQ: ONCT) * PainReform Ltd (NASDAQ: PRFX) * Pandion Therapeutics Inc (NASDAQ: PAND) * Pliant Therapeutics Inc (NASDAQ: PLRX) * Psychemedics Corp. (NASDAQ: PMD) * RA Medical Systems Inc (NYSE: RMED) * Renalytix AI PLC (NASDAQ: RNLX) * Rockwell Medical Inc (NASDAQ: RMTI) * Satsuma Pharmaceuticals Inc (NASDAQ: STSA) * SCYNEXIS Inc (NASDAQ: SCYX) * Solid Biosciences Inc (NASDAQ: SLDB) * Sonnet BioTherapeutics Holdings, Inc. (NASDAQ: SONN) * Teligent Inc (NEW JERSEY) (NASDAQ: TLGT) * Theravance Biopharma Inc (NASDAQ: TBPH) * Tricida Inc (NASDAQ: TCDA) * Vaccinex Inc (NASDAQ: VCNX) * Viveve Medical Inc (NASDAQ: VIVE) * Taro Pharmaceutical Industries Ltd. (NYSE: TARO)Stocks In Focus Novavax Commences Phase 3 Study of Coronavirus Vaccine Candidate Novavax, Inc. (NASDAQ: NVAX) said it has initiated its first Phase 3 study to evaluate the efficacy, safety and immunogenicity of NVX-CoV2373, its COVID-19 vaccine candidate.The trial is being conducted in the U.K. in partnership with the UK Government's Vaccines Taskforce, and is expected to enroll and immunize up to 10,000 individuals, ages 18-84 years, with and without relevant comorbidities, over the next four to six weeks, Novavax said.Separately, Endo International PLC (NASDAQ: ENDP) announced a non-exclusive agreement with Novavax to provide fill-finish manufacturing services at its plant in Rochester, Michigan for NVX-CoV2373.In pre-market trading Friday, Novavax shares were up 7.48% to $110.10, and Endo was gaining 9.27% to $3.30.Altimmune Rallies On Institutional Buying Altimmune Inc (NASDAQ: ALT) shares moved after a filing by the company revealed D.E. Shaw and D.E. Shaw & Co. each beneficially own 1,634,730 shares, or 5% stake in the company.The stock rallied 8.89% to $13.10 in after-hours trading.Clover Biopharma Announces Positive Preliminary Phase 1 Results From Coronavirus Vaccine Program Clover Biopharma, which is developing a protein-based COVID-19 S-Trimer vaccine candidate in combination with adjuvants from GlaxoSmithKline plc (NYSE: GSK) or Dynavax Technologies Corporation (NASDAQ: DVAX) said the investigational vaccine induced a strong immune response and protection against SARS-CoV-2 in animal models.Clover also announced preliminary results from a Phase 1 study showing that the vaccine is likely to be safe and well-tolerated, with high levels of neutralizing antibodies.Based on these preliminary results, an additional 200 participants will be enrolled in a Phase 1 dose-expansion study at the selected S-Trimer dose-level and adjuvanted with either GSK's pandemic adjuvant or Dynavax's advanced adjuvant CpG 1018 plus alum, the company said.Clover also said it plans to initiate a Phase 2/3 efficacy study before the end of 2020.Genfit Announces First Patient Visit In Pivotal Phase 3 Study of Elafibranor In Primary Biliary Cholangitis Genfit announced the first patient first visit for ELATIVE, its global, pivotal, Phase 3 study evaluating the efficacy and safety of elafibranor in primary biliary cholangitis, or PBC."This is a significant milestone and it means that we are now a step closer to hopefully bringing patients and caregivers a promising option to treat this debilitating disease and its symptoms. We see an important potential for elafibranor in PBC and will provide further information at the upcoming Corporate Update on September 30" said Pascal Prigent, CEO at GENFIT.In after-hours trading, the stock jumped 13.08% to $4.15.Radius Health, Partner Say Enrollment Into Phase 3 Study of Breast Cancer Drug Completed Radius Health Inc (NASDAQ: RDUS) and partner Menarini Group said the target enrollment milestone has been reached in the Phase 3 EMERALD clinical trial of elacestrant that is being studied in postmenopausal women and men with ER+/HER2- advanced or metastatic breast cancer.The companies expect to conduct primary analysis of data from the study in the second half of 2021. An independent data monitoring committee that reviewed results of futility analysis conducted after the completion of 70% of targeted enrollment recommended that the study proceed without modification, the companies said.Marinus Cleared to Initiate Registrational Phase 3 Study of Ganaxolone In Refractory Status Epilepticus Marinus Pharmaceuticals Inc (NASDAQ: MRNS) said it has satisfied the FDA's protocol-specific questions for the registrational Phase 3 trial of intravenous ganaxolone in refractory status epilepticus, allowing enrollment to begin in this clinical trial. The company expects the first patient to be enrolled in October and release topline data in the first half of 2022.Marinus recently reported positive Phase 3 results for ganaxolone in CDKL5 deficiency disorderIn pre-market trading, the stock was adding 5.61% to $11.30.On The Radar IPOs Prelude Therapeutics, a clinical-stage precision oncology company, priced its initial public offering, or IPO, of 8.325 million shares at $19 per share, the upper end of the estimated price range of $17-$19. Gross proceeds from the offering are expected at $158.2 million. The shares will begin trading on the Nasdaq under the ticker symbol PRLD.Greenwich LifeSciences Inc., a clinical-stage biopharma focused on the development of GP2, an immunotherapy to prevent breast cancer recurrences in patients who have previously undergone surgery, priced its IPO of 1.261 million shares at $5.75 apiece, for raising gross proceeds of $7.25 million. The shares will begin trading on the Nasdaq under the symbol GLSI.MV Pharmaceuticals, Inc., a precision oncology company, priced its IPO of 11.765 million shares at $18 per share. The shares are expected to begin trading on the Nasdaq under the ticker symbol PMVP.See more from Benzinga * The Daily Biotech Pulse: Gilead's .25B Debt Offering, Lexicon Deleverages, Taysha Gene Therapies Prices IPO * The Daily Biotech Pulse: Coronavirus Vaccine Updates From J&J & MediciNova, Australian Regulatory Nod For GW Pharma * The Daily Biotech Pulse: Legal Relief For Evolus, Fulgent to Join S&P SmallCap 600, AIM ImmunoTech's Positive Cancer Drug Readout(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
The company was once the front-runner in the race to develop a treatment for NASH, a newly defined liver disease
Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 4) * ABIOMED, Inc. (NASDAQ: ABMD) (FDA approved the emergency use of Abiomed's Impella heart pump in combination with an oxygen machine to treat Covid-19 patients who suffer heart and lung failure) * Allovir Inc (NASDAQ: ALVR) (IPOed Thursday) * Alterity Therapeutics Ltd (NASDAQ: ATHE) ( announced positive preclinical data for its lead drug in Multiple System Atrophy) * ALX Oncology Holdings Inc (NASDAQ: ALXO) * Cardiff Oncology Inc (NASDAQ: CRDF) * Cocrystal Pharma Inc (NASDAQ: COCP) (announced the publication of positive preclinical animal studies of coronavirus antiviral compounds in a medical journal) * Dr.Reddy's Laboratories Ltd (NYSE: RDY) * Fulgent Genetics Inc (NASDAQ: FLGT) * Hologic, Inc. (NASDAQ: HOLX) * Inari Medical Inc (NASDAQ: NARI) * Inozyme Pharma Inc (NASDAQ: INZY) * Quidel Corporation (NASDAQ: QDEL) * Renalytix AI PLC (NASDAQ: RNLX) * Sorrento Therapeutics Inc (NASDAQ: SRNE) * Trevena Inc (NASDAQ: TRVN) * Twist Bioscience Corp (NASDAQ: TWST) * Varian Medical Systems, Inc. (NYSE: VAR) * Zoetis Inc (NYSE: ZTS)Down In The Dumps (Biotech Stocks Hitting 52-week Lows Aug. 4) * Pandion Therapeutics Holdco LLC (NASDAQ: PAND) * Verrica Pharmaceuticals Inc (NASDAQ: VRCA)Stocks In Focus Novavax Announces Positive Phase 1 Data For Coronavirus Vaccine Novavax, Inc. (NASDAQ: NVAX) announced Phase 1 data from its Phase 1/2 randomized, observer-blinded, placebo-controlled trial of its COVID 19 vaccine NVX CoV2373 with and without Matrix M adjuvant, which showed the investigational vaccine was generally well-tolerated and elicited robust antibody responses numerically superior to that seen in human convalescent sera.Overall, the investigational vaccine was well-tolerated and had a reassuring safety profile.In after-hours trading, the stock rallied 12.62% to $177.Genfit Announces Publication of Data On Technology to Identify At-risk NASH Patients Genfit SA (NASDAQ: GNFT) said pivotal data describing the derivation and validation of NIS4 has been accepted for publication by "The Lancet Gastroenterology and Hepatology." NIS4 is GENFIT's non-invasive, blood-based diagnostic technology to identify patients with non-alcoholic steatohepatitis and significant to advanced fibrosis, also referred to as at-risk NASH in the published study."The complexity of underlying chronic liver diseases, such as NASH, is that these conditions often do not present with obvious symptoms until the disease is in very advanced stages.""Hence, we believe non-invasive testing will continue to gain importance within healthcare systems given the capability to identify those who may require more aggressive medical intervention with a simple blood draw while maintaining high diagnostic accuracy," said Suneil Hosmane, Head of Global Diagnostics at GENFIT."In pre-market trading, the stock was gaining 5.71% to $5.55.Roche Gets FDA Authorization For Quantitative Test to Detect Epstein-Barr Virus Roche Holdings AG Basel ADR Common Stock (OTC: RHHBY) said the FDA has authorized the cobas EBV test, the first quantitative in vitro diagnostic test for Epstein-Barr virus (DNA in the United States."This authorization gives healthcare professionals a key tool in monitoring transplant patients at risk for complications from infections or reactivations of EBV, by providing the ability to run a large number of patient tests for this virus in a short period of time," the company said.Aerpio Awarded $5.1M In Government Funding For A Mid-stage Study of COVID-19 Treatment Aerpio Pharmaceuticals Inc (NASDAQ: ARPO) announced an agreement with the U.S. government to evaluate its razuprotafib in a new investigational trial for the prevention and treatment of Acute Respiratory Distress Syndrome, or ARDS, in adult patients with moderate to severe COVID-19.The Medical Technology Enterprise Consortium, on behalf of the government, will provide up to $5.1 million in funding toward the clinical trial, while Aerpio will support the trial with a spending of $2.8 million.View more earnings on IBBThe partnership between Aerpio and MTEC will provide resources to support a second COVID-19 Phase 2 clinical trial, Aerpio said.The stock was jumping 44.70% to $1.91 in pre-market trading.BioNTech, Partner Fosun Begin Phase 1 Study of Coronavirus Vaccine Candidate In China BioNTech SE - ADR (NASDAQ: BNTX) and Fosun Pharma announced the first 72 participants have been dosed with BNT162b1 in a Phase 1 study in China following IND approval by the Chinese regulatory authority, National Medical Products Administration. The companies are jointly developing the COVID-19 vaccine candidate in China.The Phase 1 study, according to the companies, will evaluate safety and immunogenicity in Chinese participants to support potential regulatory approval in China.Earnings Fulgent Genetics' second-quarter revenues jumped 105% year-over-year to $17.3 million, and the non-GAAP net income increased from 6 cents per share to 17 cents per share. The results were well ahead of consensus estimates.In after-hours trading, the stock jumped 16.20% to $34.50.Rigel Pharmaceuticals, Inc.'s (NASDAQ: RIGL) second-quarter net loss per share narrowed from 12 cents in 2019 to 10 cents in 2020. Analysts, on average, had estimated a loss of 13 cents per share. Revenues increased year-over-year from $10.41 million to $16.02 million.The stock advanced 12.20% to $2.76.Vapotherm Inc (NYSE: VAPO) said its second-quarter revenues climbed 193.3% to $35.2 million. The loss per share narrowed from 76 cent in 2019 to 35 cents in 2020, while analysts expected a loss of 39 cents per share.For the third quarter, the company expects revenues of $24 million to $28 million, above the $18.65 million consensus estimate.The stock was plunging 28.44% to $37.75.On The Radar Earnings Constellation Pharmaceuticals Inc (NASDAQ: CNST) (before the market open) Vericel Corp (NASDAQ: VCEL) (before the market open) Eyepoint Pharmaceuticals Inc (NASDAQ: EYPT) (before the market open) PPD Inc (NASDAQ: PPD) (before the market open) Horizon Therapeutics PLC (NASDAQ: HZNP) (before the market open) Moderna Inc (NASDAQ: MRNA) (before the market open) Ionis Pharmaceuticals Inc (NASDAQ: IONS) (before the market open) Regeneron Pharmaceuticals Inc (NASDAQ: REGN) (before the market open) Harvard Bioscience, Inc. (NASDAQ: HBIO) (before the market open) IVERIC bio Inc (NASDAQ: ISEE) (before the market open) Brainstorm Cell Therapeutics Inc (NASDAQ: BCLI) (before the market open) BioDelivery Sciences International, Inc. (NASDAQ: BDSI) (before the market open) Allogene Therapeutics Inc (NASDAQ: ALLO (before the market open) Arena Pharmaceuticals, Inc. (NASDAQ: ARNA (after the close) ADMA Biologics Inc (NASDAQ: ADMA) (after the close) ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) (after the close) AxoGen, Inc Common Stock (NASDAQ: AXGN) (after the close) Arrowhead Pharmaceuticals Inc (NASDAQ: ARWR) (after the close) Global Blood Therapeutics Inc (NASDAQ: GBT) (after the close) Transenterix Inc (NYSE: TRXC) (after the close) Kindred Biosciences Inc (NASDAQ: KIN) (after the close) ResMed Inc. (NYSE: RMD) (after the close) Silk Road Medical Inc (NASDAQ: SILK) (after the close) Tricida Inc (NASDAQ: TCDA) (after the close) SurModics, Inc. (NASDAQ: SRDX) (after the close) Varian Medical Systems, Inc. (NYSE: VAR) (after the close) Immunomedics, Inc. (NASDAQ: IMMU) (after the close) PTC Therapeutics, Inc. (NASDAQ: PTCT) (after the close) Sangamo Therapeutics Inc (NASDAQ: SGMO) (after the close) TRACON Pharmaceuticals Inc (NASDAQ: TCON) (after the close) Lyra Therapeutics Inc (NASDAQ: LYRA) (after the close) Miragen Therapeutics Inc (NASDAQ: MGEN) (after the close) Zogenix, Inc. (NASDAQ: ZGNX) (after the close) Sarepta Therapeutics Inc (NASDAQ: SRPT) (after the close) Natera Inc (NASDAQ: NTRA) (after the close) OraSure Technologies, Inc. (NASDAQ: OSUR) (after the close) Orthopediatrics Corp (NASDAQ: KIDS) (after the close) G1 Therapeutics Inc (NASDAQ: GTHX) (after the close) Globus Medical Inc (NYSE: GMED) (after the close) TransMedics Group Inc (NASDAQ: TMDX) (after the close) Nevro Corp (NYSE: NVRO) (after the close) Collegium Pharmaceutical Inc (NASDAQ: COLL) (after the close) Endo International PLC (NASDAQ: ENDP) (after the close)See more from Benzinga * The Week Ahead In Biotech: Novavax Coronavirus Vaccine Readout, FDA Decisions And More Earnings * Attention Biotech Investors: Mark Your Calendar For August PDUFA Dates(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.